News

A study of EHR workload trends reveals a concerning increase in primary care providers' time spent in the EHR post-pandemic, with providers spending 28 more minutes each workday on EHR-related tasks now relative to 2019.

A limited number of eyes with advanced pediatric vitreoretinal diseases exhibited decreased vascular activity after intra-anterior chamber injections of ranibizumab.

This research into EDS-FLU is significant, as there remain no medications approved by the FDA for chronic rhinosinusitis without nasal polyps.

Observational data from the ARIC study reveals that lower plasma levels correlate with an increased risk of incident heart failure and diastolic dysfunction.

These data were announced by Johnson & Johnson this week and show several encouraging findings regarding guselkumab’s use among patients of different skin types.

Geovanni Faddoul, MD, discusses findings from his recent study examining the impact of induction and maintenance therapy on IgAN recurrence, graft survival, and mortality in kidney transplantation.

A new study found individuals aged 18 – 55 with treatment-resistant schizophrenia had significantly greater adverse events than individuals aged ≥ 55 years.

Sustained virologic response and several sociodemographic factors were found to be significantly associated with long-term improvements in health-related quality of life in patients with HCV.

Patients with uveitis switched from adalimumab originator to SB5 did not experience clinically significant differences in treatment efficacy and safety.

Patients on maintenance hemodialysis classified as having a high erythropoietin resistance index had a greater risk of all-cause mortality.

A significantly larger proportion of patients receiving the biosimilar QL0911 achieved a durable platelet response when compared with placebo.

Real-life data reveal the effectiveness of TNF-inhibitor biosimilars in minimizing ocular flares and preserving visual acuity in pediatric patients with uveitis.

Pivotal clinical trials associated with FDA ophthalmic drug approval were found to underreport and conflate sex and gender in analysis.

This study and its development of the Prurigo Control Test represents the first of its kind to assess chronic prurigo disease control.

Evidence from the Look AHEAD study suggests achieving remission in type 2 diabetes is associated with risk reductions in chronic kidney disease and cardiovascular disease.

A new study found individuals with OCD had an 82% increased risk of all-cause mortality as well as an increased risk of mortality due to natural causes and unnatural causes.

The XGBoost machine learning model outperformed other AI and logistic regression models for predicting DAA failure, with an AUROC of 1.000 in the training dataset and 0.803 in the validation dataset.

This interview segment with Bhatia featured a discussion on addressing both unmet needs and lack of awareness among patients with actinic keratosis.

A new study found critical components of CBT-I are cognitive restructuring, third-wave components, sleep restrictions, and stimulus control.

Patients with IgAN and urine protein levels of 0.75–3.5 g/d treated with corticosteroids exhibited significantly greater overall and complete remission rates compared to those who received supportive care.

A new study reports previously unknown inherited genetic variants that contribute to glaucoma risk among more than 11,000 people of African ancestry.

Bhatia discussed some of the major takeaways from his Winter Clinical presentation titled ‘What's New and Hot in AK Management.’

Test your knowledge of treatment persistence, adherence, and switching patterns of adalimumab biosimilar ABP 501 between adalimumab-naïve patients and adalimumab-experienced patients.

In this segment of Porter’s interview, she delves further into the phase 2 findings on lutikizumab and discusses any adverse events and future research.

Consuming a 5mg piperine capsule once daily for 12 weeks was linked to several pharmacological improvements in patients with NAFLD.

In a new study, nearly a third of participants with OSA reported using > 3 coping strategies, but participants without OSA reported never using > 3 coping strategies.

Both the FDA and EU regulators indicated visual acuity may serve as primary endpoint to evaluate MCO-010 in the treatment of low-vision retinitis pigmentosa patients.

In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.